# Clinical Utility of Methylation-based Prognostic Assay for Barrett's Esophagus

> **NCT05846971** · NA · UNKNOWN · sponsor: **Capsulomics, Inc.** · enrollment: 100 (estimated)

## Conditions studied

- Barrett Esophagus
- Esophageal Cancer

## Interventions

- **OTHER:** Educational materials on validated methylation assay

## Key facts

- **NCT ID:** NCT05846971
- **Lead sponsor:** Capsulomics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-26
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05846971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05846971, "Clinical Utility of Methylation-based Prognostic Assay for Barrett's Esophagus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05846971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*